CO-CROCS
Crocs, Inc. (NASDAQ: CROX), a global leader in innovative, casual footwear for women, men and children, today announced their latest product collaboration with multi-platinum recording artist Post Malone. This ground-breaking fourth installment of the Post Malone x Crocs collaboration series features the Post Malone x Crocs Duet Max Clog, an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005664/en/
The evolution of the Post Malone x Crocs partnership is evident over the four collaborations; consumers will see a transformation from previous designs that featured Post’s inspirations on the shoe, to this new silhouette incorporating his designs inside and out – including the detailing on the sole and straps, and the unique rope and lanyard clip feature. This next chapter in the Post Malone x Crocs partnership delivers a true creation from Post as he evolves his own aesthetic, and is eagerly anticipated by fans worldwide.
“This latest drop with Crocs is our best yet. I wanted to make a more tactical and chunky shoe, and they gave me all the tools to do just that,” said Post Malone. “I think they came out really neat, and I hope everyone loves them as much as I do.”
Along with the evolved and elevated design has been a differentiated reveal of the product to fans leading up to the launch. The brand first began teasing this new collaboration with a presence at Posty Fest in Arlington, TX in early November. In the weeks following, Crocs utilized a sequence of coordinated billboards to reveal the visual of the product and give fans an official first look at the design. The brand then made a surprise delivery of the coveted footwear last week and shared it with hundreds of fans and employees/customers of Chicken Express in Southlake, TX – the location of Post Malone’s first and only job prior to becoming a global music icon.
“After three collaborations – all selling out in minutes – we heard our fans demands for more and I’m pleased that this will be our biggest drop ever,” said Terence Reilly, Crocs Senior Vice President and Chief Marketing Officer. “We’re excited to give them another opportunity to own these limited-edition Post Malone x Crocs that are no doubt going to make waves around the planet.”
The limited-edition Post Malone x Crocs Duet Max Clog will be available online and at select retail locations around the world for $59.99 beginning December 10th , 2019 at 10:00 a.m. ET.
About Crocs, Inc.
Crocs, Inc. (Nasdaq: CROX) is a world leader in innovative casual footwear for women, men and children, combining comfort and style with a value that consumers know and love. Crocs’ proprietary Croslite™ material, a molded footwear technology, is included in the vast majority of Crocs’ collection and delivers extraordinary comfort with each step.
In 2019, Crocs declares that expressing yourself and being comfortable are not mutually exclusive. To learn more about Crocs or our global Come As You Are™ campaign, please visit www.crocs.com or follow @Crocs on Facebook, Instagram and Twitter.
About Post Malone:
A diamond-certified GRAMMY® Award-nominated phenomenon, Dallas, TX artist Post Malone regularly rewrites history, blurs boundaries, and incites internet-breaking conversation with every move. Emerging in 2015 with a genre-less brew that inspired a movement, he delivered the diamond-selling “Congratulations” [feat. Quavo], achieved back-to-back #1 debuts on the Billboard Top 200, received countless multiplatinum certifications around the world, and smashed one record after another with his Hot 100-topping hits. His 2019 third full-length, Hollywood’s Bleeding [Republic Records], represented an audience and critical high watermark. Not only did it arrive at platinum status and earn high praise from the likes of Pitchfork , but it also reigned at #1 on the Billboard Top 200 for four weeks and returned to the chart for a fifth week, making for the longest run atop the chart of 2019 and the first release to do so in over a year. It followed the immense success of the triple-platinum beerbongs & Bentleys , which also landed at #1 a year prior. In the wake of beerbongs & Bentleys , Post crushed a record in place for 54 years. He charted nine songs in the Top 20 of the Hot 100, notching “the most songs in the Top 20 of the Hot 100 ever .” Moreover, he also trounced the record for most simultaneous Top 40 Hot 100 hits with 14.
As of 2019, his catalog comprises the GRAMMY® Award-nominated “rockstar” [feat. 21 Savage] (8x-platinum), “Sunflower (Spider-Man: Into The Spider-Verse )” [feat. Swae Lee] (8x-platinum), “I Fall Apart” (5x-platinum), “Psycho” [feat. Ty Dolla $ign] (5x-platinum), “White Iverson” (5x-platinum), “Better Now” (4x-platinum), and more. Not to mention, he sold out numerous arena tours and launched his own mega-popular Posty Fest in its second successful year in 2019. It all started with his triple-platinum influential 2016 debut, Stoney . With records under his belt that will likely never be surpassed and a generation of artists and audiences worldwide under his spell, Post Malone simply doesn’t stop.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005664/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom